This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 1995 Apr;23(2):231-5.

doi: 10.1007/BF02354274.

Commentary on "Physiologically based pharmacokinetic modeling as a tool for drug development"

T M Ludden¹, W R Gillespie, W J Bachman

Affiliations

PMID: 8719239
DOI: 10.1007/BF02354274

Comment

Commentary on "Physiologically based pharmacokinetic modeling as a tool for drug development"

T M Ludden et al. J Pharmacokinet Biopharm. 1995 Apr.

. 1995 Apr;23(2):231-5.

doi: 10.1007/BF02354274.

Authors

T M Ludden¹, W R Gillespie, W J Bachman

Affiliation

¹ Division of Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA.

PMID: 8719239
DOI: 10.1007/BF02354274

No abstract available

PubMed Disclaimer

Comment on

Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.
Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H. Charnick SB, et al. J Pharmacokinet Biopharm. 1995 Apr;23(2):217-29. doi: 10.1007/BF02354273. J Pharmacokinet Biopharm. 1995. PMID: 8719238 Review.

Similar articles

Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.
Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H. Charnick SB, et al. J Pharmacokinet Biopharm. 1995 Apr;23(2):217-29. doi: 10.1007/BF02354273. J Pharmacokinet Biopharm. 1995. PMID: 8719238 Review.
Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.
Moss DM, Marzolini C, Rajoli RK, Siccardi M. Moss DM, et al. Expert Opin Drug Metab Toxicol. 2015;11(8):1203-17. doi: 10.1517/17425255.2015.1037278. Epub 2015 Apr 15. Expert Opin Drug Metab Toxicol. 2015. PMID: 25872900 Review.
Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction.
Galetin A, Zhao P, Huang SM. Galetin A, et al. J Pharm Sci. 2017 Sep;106(9):2204-2208. doi: 10.1016/j.xphs.2017.03.036. Epub 2017 Apr 5. J Pharm Sci. 2017. PMID: 28390843 Review.
Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach.
Allegaert K, Smits A, van den Anker JN. Allegaert K, et al. J Biomed Biotechnol. 2012;2012:103763. doi: 10.1155/2012/103763. Epub 2012 Mar 5. J Biomed Biotechnol. 2012. PMID: 22500073 Free PMC article. No abstract available.
Have physiologically-based pharmacokinetic models delivered?
Edginton AN, Joshi G. Edginton AN, et al. Expert Opin Drug Metab Toxicol. 2011 Aug;7(8):929-34. doi: 10.1517/17425255.2011.585968. Expert Opin Drug Metab Toxicol. 2011. PMID: 21762039

See all similar articles

Cited by

The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'.
Williams PJ, Ette EI. Williams PJ, et al. Clin Pharmacokinet. 2000 Dec;39(6):385-95. doi: 10.2165/00003088-200039060-00001. Clin Pharmacokinet. 2000. PMID: 11192472 Review.
Pharmacokinetic-pharmacodynamic guided trial design in oncology.
van Kesteren Ch, Mathôt RA, Beijnen JH, Schellens JH. van Kesteren Ch, et al. Invest New Drugs. 2003 May;21(2):225-41. doi: 10.1023/a:1023577514605. Invest New Drugs. 2003. PMID: 12889741 Review.

References

1. J Pharmacokinet Biopharm. 1991 Jun;19(3):319-31 - PubMed
1. J Pharmacokinet Biopharm. 1989 Aug;17(4):463-91 - PubMed
1. J Pharmacokinet Biopharm. 1994 Aug;22(4):259-92 - PubMed
1. J Pharmacokinet Biopharm. 1995 Apr;23(2):217-29 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions